Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma

Cecilia Parrula, Soledad A. Fernandez, Bevin Zimmerman, Michael Dale Lairmore, Stefan Niewiesk

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Adult T-cell leukaemia/lymphoma (ATL) is a highly aggressive CD4+ T-cell malignancy caused by human T-cell leukaemia virus type 1. Measles virus (MV) oncolytic therapy has been reported to be efficient in reducing tumour burden in subcutaneous xenograft models of lymphoproliferative disorders such as myeloma, B-cell lymphoma and cutaneous T-cell lymphoma, but its potential to reduce tumour burden in disseminated lymphoproliferative disorders such as ATL remains to be determined. In this study, MV oncolytic therapy was evaluated in the MET-1/NOD/SCID xenograft mouse model of ATL. Treatment with the vaccine-related strain MV-NSE led to a significant reduction in tumour burden. In mice with a high tumour burden, therapy with MV-NSE significantly increased survival beyond any other single treatment tested previously using this model. Interestingly, signs of morbidity (cachexia) in mice treated with MV were not directly associated with tumour burden, but were correlated with the secretion of interleukin-6 by MET-1 cells and host cells. The results suggest that MV therapy could be a promising therapy for generalized lymphoproliferative disease.

Original languageEnglish (US)
Pages (from-to)1458-1466
Number of pages9
JournalJournal of General Virology
Volume92
Issue number6
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
Measles virus
Measles
Tumor Burden
Lymphoproliferative Disorders
Heterografts
Deltaretrovirus
Therapeutics
Cutaneous T-Cell Lymphoma
Cachexia
SCID Mice
B-Cell Lymphoma
Interleukin-6
Vaccines
Morbidity
T-Lymphocytes
Neoplasms

ASJC Scopus subject areas

  • Virology

Cite this

Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma. / Parrula, Cecilia; Fernandez, Soledad A.; Zimmerman, Bevin; Lairmore, Michael Dale; Niewiesk, Stefan.

In: Journal of General Virology, Vol. 92, No. 6, 06.2011, p. 1458-1466.

Research output: Contribution to journalArticle

Parrula, Cecilia ; Fernandez, Soledad A. ; Zimmerman, Bevin ; Lairmore, Michael Dale ; Niewiesk, Stefan. / Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma. In: Journal of General Virology. 2011 ; Vol. 92, No. 6. pp. 1458-1466.
@article{744154bc9e90493c8a772253c6d9a417,
title = "Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma",
abstract = "Adult T-cell leukaemia/lymphoma (ATL) is a highly aggressive CD4+ T-cell malignancy caused by human T-cell leukaemia virus type 1. Measles virus (MV) oncolytic therapy has been reported to be efficient in reducing tumour burden in subcutaneous xenograft models of lymphoproliferative disorders such as myeloma, B-cell lymphoma and cutaneous T-cell lymphoma, but its potential to reduce tumour burden in disseminated lymphoproliferative disorders such as ATL remains to be determined. In this study, MV oncolytic therapy was evaluated in the MET-1/NOD/SCID xenograft mouse model of ATL. Treatment with the vaccine-related strain MV-NSE led to a significant reduction in tumour burden. In mice with a high tumour burden, therapy with MV-NSE significantly increased survival beyond any other single treatment tested previously using this model. Interestingly, signs of morbidity (cachexia) in mice treated with MV were not directly associated with tumour burden, but were correlated with the secretion of interleukin-6 by MET-1 cells and host cells. The results suggest that MV therapy could be a promising therapy for generalized lymphoproliferative disease.",
author = "Cecilia Parrula and Fernandez, {Soledad A.} and Bevin Zimmerman and Lairmore, {Michael Dale} and Stefan Niewiesk",
year = "2011",
month = "6",
doi = "10.1099/vir.0.028910-0",
language = "English (US)",
volume = "92",
pages = "1458--1466",
journal = "Journal of General Virology",
issn = "0022-1317",
publisher = "Society for General Microbiology",
number = "6",

}

TY - JOUR

T1 - Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma

AU - Parrula, Cecilia

AU - Fernandez, Soledad A.

AU - Zimmerman, Bevin

AU - Lairmore, Michael Dale

AU - Niewiesk, Stefan

PY - 2011/6

Y1 - 2011/6

N2 - Adult T-cell leukaemia/lymphoma (ATL) is a highly aggressive CD4+ T-cell malignancy caused by human T-cell leukaemia virus type 1. Measles virus (MV) oncolytic therapy has been reported to be efficient in reducing tumour burden in subcutaneous xenograft models of lymphoproliferative disorders such as myeloma, B-cell lymphoma and cutaneous T-cell lymphoma, but its potential to reduce tumour burden in disseminated lymphoproliferative disorders such as ATL remains to be determined. In this study, MV oncolytic therapy was evaluated in the MET-1/NOD/SCID xenograft mouse model of ATL. Treatment with the vaccine-related strain MV-NSE led to a significant reduction in tumour burden. In mice with a high tumour burden, therapy with MV-NSE significantly increased survival beyond any other single treatment tested previously using this model. Interestingly, signs of morbidity (cachexia) in mice treated with MV were not directly associated with tumour burden, but were correlated with the secretion of interleukin-6 by MET-1 cells and host cells. The results suggest that MV therapy could be a promising therapy for generalized lymphoproliferative disease.

AB - Adult T-cell leukaemia/lymphoma (ATL) is a highly aggressive CD4+ T-cell malignancy caused by human T-cell leukaemia virus type 1. Measles virus (MV) oncolytic therapy has been reported to be efficient in reducing tumour burden in subcutaneous xenograft models of lymphoproliferative disorders such as myeloma, B-cell lymphoma and cutaneous T-cell lymphoma, but its potential to reduce tumour burden in disseminated lymphoproliferative disorders such as ATL remains to be determined. In this study, MV oncolytic therapy was evaluated in the MET-1/NOD/SCID xenograft mouse model of ATL. Treatment with the vaccine-related strain MV-NSE led to a significant reduction in tumour burden. In mice with a high tumour burden, therapy with MV-NSE significantly increased survival beyond any other single treatment tested previously using this model. Interestingly, signs of morbidity (cachexia) in mice treated with MV were not directly associated with tumour burden, but were correlated with the secretion of interleukin-6 by MET-1 cells and host cells. The results suggest that MV therapy could be a promising therapy for generalized lymphoproliferative disease.

UR - http://www.scopus.com/inward/record.url?scp=79956326731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956326731&partnerID=8YFLogxK

U2 - 10.1099/vir.0.028910-0

DO - 10.1099/vir.0.028910-0

M3 - Article

C2 - 21325484

AN - SCOPUS:79956326731

VL - 92

SP - 1458

EP - 1466

JO - Journal of General Virology

JF - Journal of General Virology

SN - 0022-1317

IS - 6

ER -